Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review

被引:3
|
作者
Perera, Sachin [1 ,4 ]
McDonald, Jodie [1 ,2 ,3 ]
Williams, Isabella [1 ]
O'Brien, Jonathan [2 ,3 ]
Murphy, Declan [2 ,3 ]
Lawrentschuk, Nathan [1 ,4 ]
机构
[1] Univ Melbourne, Dept Urol, Royal Melbourne Hosp, Melbourne, Vic, Australia
[2] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Div Canc Surg, Melbourne, Vic, Australia
[4] EJ Whitten Fdn Prostate Canc Res Ctr Epworth, Melbourne, Vic, Australia
关键词
Active surveillance; low risk; nonradical treatment; progression; prostate cancer; survival; DUTASTERIDE; CARE;
D O I
10.1016/j.prnil.2022.08.002
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Low-risk prostate cancer has traditionally seen a preference towards avoiding treatment-related harms with active surveillance (AS) and multimodal monitoring protocols utilized to assess for disease progression. Large trials have shown variations in mortality and cancer survival benefit between AS and radical treatment, which has prompted further trials into the management of low-risk disease. Non-radical treatments for men on AS have been an emerging field and yet to enter mainstream guidelines or practice. These include pharmacological treatments, focal therapy, nutraceuticals, immunotherapy, and exercise. We present a review of all current major randomized clinical trials for nonradical treatment of men on AS and summarize their findings. (C) 2022 Asian Pacific Prostate Society. Publishing services by Elsevier B.V.
引用
收藏
页码:117 / 122
页数:6
相关论文
共 50 条
  • [1] Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer
    Taylor, Kathryn L.
    Hoffman, Richard M.
    Davis, Kimberly M.
    Luta, George
    Leimpeter, Amethyst
    Lobo, Tania
    Kelly, Scott P.
    Shan, Jun
    Aaronson, David
    Tomko, Catherine A.
    Starosta, Amy J.
    Hagerman, Charlotte J.
    Van Den Eeden, Stephen K.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (08) : 1240 - 1250
  • [2] Active surveillance for men with low-risk prostate cancer
    Sturch, Paul
    Kirby, Roger
    Challacombe, Ben
    [J]. TRENDS IN UROLOGY & MENS HEALTH, 2014, 5 (02) : 14 - 16
  • [3] Re: Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer
    Penson, David F.
    [J]. JOURNAL OF UROLOGY, 2017, 197 (01): : 153 - 153
  • [4] Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer
    Olsson, Henrik
    Nordstrom, Tobias
    Clements, Mark
    Gronberg, Henrik
    Lantz, Anna Wallerstedt
    Eklund, Martin
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (05): : 640 - 647
  • [5] Active Surveillance for Black Men With Low-Risk Prostate Cancer
    Shen, Xinglei
    Pettaway, Curtis A.
    Chen, Ronald C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (17): : 1733 - 1734
  • [6] THE QUALITY OF ACTIVE SURVEILLANCE FOR MEN WITH LOW-RISK PROSTATE CANCER
    Levy, Mya E.
    Meyers, Stephanie
    Wood, David P.
    Montie, James E.
    Miller, David C.
    Wei, John T.
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 179 - 179
  • [7] USE OF HOLEP IN MEN ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER
    Schober, Jared
    Stensland, Kristian
    Mandeville, Jessica
    Moinzadeh, Alireza
    Canes, David
    [J]. JOURNAL OF UROLOGY, 2020, 203 : E1188 - E1188
  • [8] Enzalutamide versus active Surveillance in Patients with Low-risk Prostate Cancer
    Dunst, Juergen
    Krug, David
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 (02) : 201 - 203
  • [9] Surveillance biopsy and active treatment during active surveillance for low-risk prostate cancer
    Katsuyoshi Hashine
    Hiroyuki Iio
    Yoshiteru Ueno
    Shohei Tsukimori
    Iku Ninomiya
    [J]. International Journal of Clinical Oncology, 2014, 19 : 531 - 535
  • [10] Active surveillance for low-risk prostate cancer
    Herlemann, Annika
    Stief, Christian G.
    [J]. UROLOGE, 2016, 55 (02): : 269 - 278